Aquestive Therapeutics Community
NasdaqGM:AQST Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
Community Investing Ideas
AN
Consensus Narrative from 9 Analysts
FDA Approval And Anaphylm Launch Will Expand Global Reach
Key Takeaways Success in FDA approval for Anaphylm and Libervant expansion could significantly boost revenue and market penetration. Targeting international markets and developing new treatments offer potential revenue diversification and growth opportunities.
View narrativeUS$9.86
FV
71.7% undervalued intrinsic discount21.17%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
9 days ago author updated this narrative